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Abstract 
Migraine is a common and highly disabling neurological disorder associated with a high socioeconomic burden. 
Effective migraine management depends on adequate patient education: to avoid unrealistic expectations, the con-
dition must be carefully explained to the patient soon as it is diagnosed. The range of available acute treatments has 
increased over time. At present, abortive migraine therapy can be classed as specific (ergot derivatives and triptans) 
or non-specific (analgesics and non-steroidal anti-inflammatory drugs). Even though acute symptomatic therapy 
can be optimised, migraine continues to be a chronic and potentially progressive condition. In addition to the drugs 
officially approved for migraine prevention by international governmental regulatory agencies, numerous different 
agents are commonly used for this indication, showing various levels of evidence of efficacy and tolerability. Guide-
lines published in recent years, based on evidence-based medicine data on migraine prophylaxis, are a useful source 
of guidance, especially for primary care physicians and neurologists without specific expertise in headache medi-
cine. Although the field of pharmacological migraine prevention has seen few advances in recent years, potential 
novel approaches are now being developed. This review looks at emerging pharmacological strategies for acute and 
preventive migraine treatment that are nearing or have already entered the clinical trial phase. Specifically, it discusses 
preclinical and clinical data on compounds acting on calcitonin gene-related peptide or its receptor, the serotonin 
5-HT1F receptor, nitric oxide synthase, and acid-sensing ion channel blockers.
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Migraine is a common and highly disabling primary 
headache form associated with a high socioeconomic 
burden and a generally high prevalence. Its prevalence is 
highest in the Americas, followed by Europe, whereas it 
is lower in Africa and Asia (Lipton et al. 2001).
Updated government statistics on the prevalence and 
burden of migraine and severe headache in the US indi-
cate that migraine headaches affect around one in seven 
Americans annually (Burch et  al. 2015), while summa-
rised data from a review of headache and migraine in 
Europe showed the mean prevalence of current migraine 
among 170,000 adults to be 14.7  % (8  % in men and 
17.6 % in women) (Lars and Colette 2010).
As regards the classification of migraine, the latest ver-
sion of the International Headache Society’s International 
Classification of Headache Disorders, ICHD-III (beta) 
(Headache Classification Committee of the International 
Headache Society (IHS) 2013), contains a series of impor-
tant changes, e.g. chronic migraine, previously classi-
fied as a complication of migraine, is now considered a 
migraine subcategory. Furthermore, the new version 
stipulates that patients with headache (tension-type-like 
and/or migraine-like) occurring on 15 or more days per 
month for more than 3  months, bearing the features of 
migraine headache on at least 8  days per month, must 
be classified as affected by chronic migraine (Headache 
Classification Committee of the International Headache 
Society (IHS) 2013). In this way the classification defines 
migraine according to attack frequency, and thus gives 
prominence to the most serious headache forms within 
the migraine spectrum.
Medication overuse is a major risk in chronic migraine; 
indeed, frequent use of some migraine medications can 
lead to the development of a disabling condition termed 
medication-overuse headache (MOH). In such cases, 
the overused drug needs to be withdrawn, after which 
the migraine will either revert to the episodic subtype or 
remain chronic, and must be re-diagnosed accordingly. 
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Patients found to meet the criteria both for chronic 
migraine and for MOH should receive both diagnoses 
(Headache Classification Committee of the International 
Headache Society (IHS) 2013).
The initial diagnosis of migraine can be facilitated 
by the mnemonic POUND—pulsatile headache, 1-day 
duration (4–72  h), unilateral location, nausea or vomit-
ing, and disabling intensity—, an evidence-based aid that 
summarises some of the main features of the condition.
A detailed medical history and neurological examina-
tion can then help confirm the diagnosis and rule out 
secondary conditions. Secondary headaches account 
for only a minority of headache diagnoses, but they can 
indicate the presence of severe, life-threatening condi-
tions. Although prospective studies are lacking, there are 
various historical and physical features that, on the basis 
of extensive clinical experience, must be considered red 
flags for serious problems in this regard. It is important 
to look out for: older or younger age at onset (>50 years 
or <10  years); changes in presentation (increase in fre-
quency and severity, headache that is worse than or 
different from the usual headache, precipitation of 
headache by Valsalva manoeuvres, progressive head-
ache thunderclap headache; atypical or prolonged aura; 
first-ever onset of aura in women taking a combined oral 
contraceptive; concurrent systemic illness or systemic 
symptoms; abnormalities on neurological examination 
(Hainer and Matheson 2013; Dodick 1997; Orr et  al. 
2015).
Effective management of migraine depends on the pro-
vision of adequate patient education: to avoid unrealistic 
expectations, the condition must be carefully explained 
to the patient soon as it is diagnosed. Patient-compiled 
headache diaries can be very valuable tools for planning 
and evaluating treatment.
Migraine treatment traditionally includes both pre-
ventive therapy, aimed at reducing attack frequency and 
severity, and acute therapy, for aborting attacks.
Primarily, patients want to obtain faster onset of relief 
and more complete relief, without recurrences or adverse 
events. Accordingly, acute migraine treatment of a single 
attack seeks to provide rapid and definitive relief, with 
only minimal or no adverse events, and thus to promptly 
restore the patient’s ability to function (Silberstein et al. 
2012a).
To achieve all this, it is necessary to follow several gen-
eral rules: it is crucial to intervene early, when the pain 
is still mild, and to use adequate drug doses and appro-
priate routes of administration; antiemetic or prokinetic 
drugs should be co-administered to facilitate absorption 
of the primary drug; it is also important to take steps to 
avoid chronification of the headache and the develop-
ment of MOH.
The two main approaches to migraine management 
are stratified care, which depends on the severity of the 
disease and assessment of other factors, and step care, 
in which patients are initially administered simple anal-
gesics, but may subsequently need to progress to more 
powerful drugs (Lipton et al. 2000).
Symptomatic therapy
The choice of acute treatment has increased over time. At 
present, the drugs that have shown efficacy in migraine 
attack therapy can be divided into: non-specific drugs 
(analgesics and non-steroidal anti-inflammatory drugs—
NSAIDs) and specific drugs (ergot derivatives and 
triptans).
We here discuss the efficacy and safety of acute 
migraine drugs with reference to the recommendations 
contained in the European Federation of Neurological 
Societies guideline (Evers et al. 2009) and the guidelines 
of the American Academy of Neurology (Marmura et al. 
2015).
On the basis of the quality of available studies, each 
acute migraine drug is assigned a level of evidence: level 
A, established as effective (or ineffective); level B, proba-
bly effective (or ineffective); level C, possibly effective (or 
ineffective); level U, evidence is conflicting or inadequate 
to support or refute the use of the medication(s).
Non‑specific drugs (analgesics and NSAIDs)
Despite growing use of the more recently introduced 
triptans, NSAIDs remain the most commonly used acute 
migraine treatments. A study examining migraine treat-
ment patterns in the US population showed that nearly 
all (98 %) migraineurs used acute treatments, with 49 % 
using over-the-counter (OTC) medication only, 20  % 
using prescription medication only, and 29 % using both. 
The OTC medications included aspirin, other NSAIDs, 
paracetamol (acetaminophen), and paracetamol with 
caffeine (Diamond et al. 2007; Lipton et al. 2007). Large 
studies in France and Germany gave similar results 
(Lucas et al. 2006; Radtke and Neuhauser 2009).
Analgesics and NSAIDs are the drugs of first choice for 
mild or moderate migraine.
Phenazone 1000  mg (Göbel et  al. 2004), metamizole 
1000 mg (dipyrone) (Tulunay et al. 2004) and tolfenamic 
acid 200  mg have been shown to be effective acute 
migraine drugs (level B recommendation) (Evers et  al. 
2009). Acetaminophen alone is not recommended for 
moderate-to-severe migraine (level B recommenda-
tion) (Silberstein and US Headache Consortium 2000), 
although it can be used, at a dose of 1000  mg, for mild 
migraine (level A recommendation).
Acetylsalicylic acid (ASA), in doses of up to 1000  mg 
(Diener et al. 2004), ibuprofen (200–800 mg), diclofenac 
Page 3 of 14Antonaci et al. SpringerPlus  (2016) 5:637 
(50–100 mg) and naproxen sodium (500–1000 mg) (Evers 
et al. 2009; Suthisisang et al. 2010) are also effective (level 
A recommendation).
The fixed combination of ASA (250  mg), paracetamol 
(200 mg) and caffeine (50 mg) is more effective than these 
agents administered alone (Diener et al. 2005).
The oral combination of indomethacin, caffeine 
and prochlorperazine showed similar efficacy to oral 
sumatriptan, whereas its rectal formulation proved supe-
rior to oral sumatriptan (Sandrini et  al. 2007). Patients 
using caffeine-containing drugs should be carefully mon-
itored as they are more likely to develop rebound head-
ache; caffeine can also contribute to the chronification 
process (Silbertsien and Strirpe 2014).
Antiemetics and prokinetics (such as domperidone 
10 mg orally, metoclopramide 10 mg orally and prochlor-
perazine 3 mg orally) are indicated in addition to analge-
sics or NSAIDs for attacks accompanied by severe nausea 
and vomiting. Formulations containing NSAIDs (ASA or 
paracetamol) and metoclopramide are available in some 
countries, and paracetamol (1000 mg) in association with 
metoclopramide (10  mg) is superior to placebo (Evers 
et al. 2009).
Recent studies have shown that NSAIDs can also be 
administered by other routes. In a Class II study evaluat-
ing an intranasal formulation of ketorolac tromethamine 
200  mg, containing 6  % lidocaine, for acute treatment 
(within 4 h of attack onset) of migraine with and with-
out aura (Faffenrath et  al. 2012) showed no significant 
difference in freedom from headache at 2 h between the 
ketorolac and placebo groups; however, ketorolac gave 
superior results on several secondary outcome meas-
ures, including lack of disability at 2 h and 2-h headache 
relief.
Intra-oral topical ketoprofen gel applied to a branch 
of the trigeminal nerve is being analysed in an ongoing 
randomised controlled trial (RCT) versus placebo (Behar 
2011).
In a recent RCT (Lipton et al. 2010), a powder formu-
lation of diclofenac potassium, to be dissolved in water, 
showed good efficacy in the treatment of moderate-to-
severe migraine attacks.
Intravenous ibuprofen (800  mg) is undoubtedly a 
promising new NSAID formulation whose efficacy, ver-
sus placebo, as an acute migraine treatment is currently 
being investigated in an ongoing RCT (Latsko and Brad-
ley 2015).
Etodolac is a new NSAID that showed good efficacy 
versus paracetamol in a recent RCT in 229 patients 
(Öztürk et al. 2013).
Several of the COX-2-specific inhibitors have also been 
studied as anti-migraine drugs. Rofecoxib and valdecoxib 
were both found to be effective but were subsequently 
withdrawn from the market due to concerns over an 
increased cardiovascular risk (Saper et  al. 2006; Silber-
stein et al. 2004). Celecoxib 400 mg is still available and 
relieves acute migraine pain with the same efficacy as 
naproxen sodium 500 mg (Loo et al. 2007).
Several combinations of NSAIDs and triptans have 
been studied and the FDA has approved the combination 
of sumatriptan 85 mg and naproxen sodium 500 mg. This 
combination is superior to each of the agents used alone 
(Marmura et al. 2015).
In order to prevent the development of MOH, the 
intake of simple analgesics should be restricted to 15 days 
per month, and combined analgesics used on no more 
than 10 days per month.
Table  1 provides an overview of analgesics used in 
acute migraine treatment together with their levels of 
recommendation.
The use of NSAIDs is contraindicated in patients with 
peptic ulcer and haemorrhagic diathesis. The long-term 
side effects (especially gastric symptoms) associated with 
ASA and other NSAIDs are well documented. However, 
in short-term trials ASA was generally well tolerated. 
NSAIDs have consistently shown lower overall adverse 
event rates (in particular, lower rates of nausea and vom-
iting) when compared with ergotamine.
Specific anti‑migraine drugs
Ergot derivatives (ergotamine tartrate 
and dihydroergotamine)
The ergot derivatives exert an anti-migraine effect as a 
result of their agonist action on serotonin (5-HT) recep-
tors, a mechanism of action shared by the triptans. Ergot-
amine, introduced in 1926, was the first drug used for 
acute migraine treatment. It remains a popular sympto-
matic migraine drug, probably because it is inexpensive 
and has a long duration of action. Ergotamine is used in 
the treatment of long-lasting attacks with tendency to 
headache recurrence (return of pain after initial treat-
ment success). It is available in different formulations: 
oral tablet (0.5–2  mg), suppository (1–2  mg) and as a 
formulation for inhalation (maximum dosage 1.8  mg). 
In some countries it is used alone, although the supposi-
tory formulation usually contains a combination of ergot-
amine and caffeine.
The vasoconstrictor effect of ergotamine contraindi-
cates its use in uncontrolled hypertension, coronary heart 
disease, peripheral vascular diseases, stroke, impaired 
hepatic or renal function, and pregnancy.
Because of their complex pharmacology and prolonged 
interaction with many other receptors (5-HT1A, 5-HT5, 
5-HT2, 5-HT7, α-adrenoceptors and dopamine D2 
receptors), which outlasts their long duration of action, 
ergot derivatives generate frequent and various adverse 
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effects (most commonly nausea and vomiting, but also 
cramps, sleepiness and transient lower limb muscle pain). 
Ergotamine should not be taken within 6  h of triptans, 
and similarly triptans should not be administered within 
24 h of ergotamine.
Dihydroergotamine (DHE) is usually better tolerated 
than ergotamine, but less effective due to its poor oral 
bioavailability. Intranasal DHE has better bioavailability 
(about 40 %), but a relatively slow onset of action. In two 
trials it was clearly shown to be inferior to intranasal and 
subcutaneous sumatriptan (Boureau et al. 2000; Touchon 
et al. 1996). Parenteral DHE, i.e. administered as a solu-
tion that can be injected intravenously or subcutaneously, 
is more effective in severe migraine attacks but produces 
more side effects (Colman et al. 2005).
A major problem with ergot derivatives is ergotamine-
induced headache and rebound headache associated with 
frequent use. These problems can be limited by introduc-
ing a preventive therapy as the headache becomes more 
frequent. However, ergotamine can no longer be consid-
ered a drug of choice as it carries a high risk of overuse.
Triptans
Introduced nearly 25  years ago, the triptans, a class of 
selective and highly effective 5-HT1B/1D receptor ago-
nists, have now largely replaced the ergot derivatives.
The triptans are potent vasoconstrictors that seem to 
act on migraine by three main mechanisms: (1) intrac-
ranial extracerebral vasoconstriction, and inhibition of 
neurotransmitter release at both peripheral and central 
trigeminal nociceptive terminals, mainly via 5-HT1B/1D 
receptors (trigeminovascular afferents and trigeminal 
nucleus caudalis).
Sumatriptan, introduced in 1991, is the oldest drug 
in this class and still regarded as the gold standard 
(McCrory and Gray 2003; Winner et al. 2005), however, it 
has several drawbacks: low bioavailability, a short plasma 
half-life and low liposolubility. The six second-gener-
ation triptans (zolmitriptan, naratriptan, rizatriptan, 
almotriptan, eletriptan and frovatriptan), which entered 
the market more recently, show better pharmacokinetic 
properties (Table 2).
The pharmacokinetic differences between the various 
triptans influence their use in clinical practice (Table 3).
The efficacy of the triptans in migraine attack treat-
ment has been extensively investigated in randomised, 
double-blind, placebo-controlled clinical trials, which 
have also attempted to define their optimal doses.
The measures of efficacy used in this context include: 
degree of pain relief, pain freedom at 2  h, sustained 
pain freedom (defined as pain-free at 2  h plus no use 
of rescue medication and no recurrence within 24  h), 
and sustained pain freedom associated with no adverse 
events.
The main literature findings are summarised below.
Sumatriptan
As shown by the results of systematic reviews and meta-
analyses (Derry et  al. 2012), the subcutaneous, oral and 
intranasal preparations of sumatriptan have shown evi-
dence of efficacy in randomised, placebo-controlled tri-
als of acute migraine therapies; furthermore, in a single 
placebo-controlled trial, the novel transdermal formula-
tion was also found to be effective (Goldstein et al. 2012). 
Subcutaneous sumatriptan (6  mg) has the fastest onset 
of action and is more effective than oral sumatriptan 
Table 1 Analgesics and non‑steroidal anti‑inflammatory drugs (NSAIDS) in migraine treatment
Substances Dosages (mg) Route(s) of  
administration




Acetylsalicylic acid (ASA) 325–650 Oral 4000 A
300–600 Suppository
1000 Intravenous 4000 A
Ibuprofen 200–800 oral Oral 3400 A
Naproxen sodium 250–750 oral Oral 1250 A
Diclofenac 50–100 oral Oral 150
Paracetamol  
(acetaminophen)
325–1000 Oral 4000 A
325–1000 Suppository 4000
Metamizol (dipyrone) 250–1000 Oral 4000 B
500–1000 Intravenous
Phenazone 500–1000 Oral 4000 B
500–1000 Suppository 4000
Tolfenamic acid 200 mg Oral 4000 B
ASA + acetaminophen + caffeine 250 + 200 + 50 2000 + 1600 + 400 B
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(100 mg), but it is associated with more frequent adverse 
events. Oral sumatriptan is most effective at 100  mg, 
although the 50 mg dose may provide the best combina-
tion of efficacy and tolerability (Evers et al. 2009).
A sumatriptan transdermal patch was recently mar-
keted; the dose delivered by the patch penetrates the skin 
using an electric gradient system (Schulman et al. 2010; 
Smith et  al. 2011). Transdermal iontophoretic delivery 
of sumatriptan may offer migraine patients significant 
clinical benefits. Indeed, it is less likely to aggravate the 
gastrointestinal disturbances associated with migraine; 
furthermore, it is able to guarantee consistent, predict-
able delivery of desired drug levels over a 4-h period, and 
may avoid the atypical pain, pressure and other sensa-
tions commonly associated with current triptan formula-
tions (Pierce et al. 2009).
A sumatriptan lingual spray, currently under devel-
opment, has shown a good bioequivalence with oral 
sumatriptan 50 mg (Dilone et al. 2009).
Zolmitriptan
The efficacy of zolmitriptan as an acute migraine therapy 
has been shown by number of randomised, placebo-con-
trolled trials, as well as by a meta-analysis. The optimal 
starting dose seemed to be 2.5 mg (Bird et al. 2014).
Naratriptan
According to least three randomised trials, naratriptan 
provides significantly better acute migraine relief than 
placebo does. In one of the studies, 2.5  mg was the 
most effective dose for producing headache relief at 4 h, 
showing an adverse event rate similar to that of placebo 
(Havanka et al. 2000; Stark et al. 2000).
Rizatriptan
A systematic review of seven randomised, placebo-
controlled studies involving 3528 patients (Winner 
et al. 2003) showed that rizatriptan is an effective acute 
migraine treatment. Rizatriptan (both 5 and 10  mg), 
compared with placebo, provided a significant benefit 
in all five main efficacy outcomes (ranging from relief at 
1–24  h) (Oldman et  al. 2001). The 10  mg dose was the 
more effective; 5 mg is indicated if the patient is taking 
beta-blockers. Rizatriptan is the oral triptan with the 
fastest onset of efficacy (30 min) and the fastest time to 
peak plasma levels (60 min), but it also has the shortest 
plasma half-life (2–2.5 h).
Eletriptan
In a meta-analysis of six randomised, controlled trials of 
eletriptan involving 3224 patients, eletriptan at doses of 
20, 40, and 80 mg performed significantly better than pla-
cebo for all the main outcomes (Pringsheim and Becker 
Table 2 The pharmacokinetic properties of the available triptans
SI subcutaneous injection, OT oral tablet, NS nasal spray, ODT oral dispersible tablet, min minutes, h hour










Sumatriptan SI 6 6 12 min 2 97
OT 50–100 200 2–3 h 2 15
NS 20 40 1 h 2 17
Rizatriptan ODT 10 30 1–2 h 2 14
Zolmitriptan ODT 2.5 10 3 h 2.5–3 40–50
Almotriptan OT 12.5 12.5 1.5–2 h 3.5 70
Eletriptan OT 40 80 1.5–2 h 4 50
Naratriptan OT 2.5 5 2–3 h 6 60–70
frovatriptan OT 2.5 7.5 2–4 h 26 20–40
Table 3 Use of the different triptans in clinical practice
SI subcutaneous injection, OT oral tablet, NS nasal spray, ODT oral dispersible 
tablet, S suppository
Drug Formulation Use in clinical practice




Rizatriptan ODT Fast acting; if nausea/vomiting
OT
Zolmitriptan ODT If nausea/vomiting
OT
NS If nausea/vomiting
Almotriptan OT Previous adverse events
Eletriptan OT
Naratriptan OT Previous adverse events
Long-lasting attacks
Frovatriptan OT Long-lasting attacks
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2014). Pain relief was dose dependent, with 80 mg found 
to provide statistically significantly greater pain relief 
than 40 mg at both 2 and 24 h (Smith et al. 2001).
Frovatriptan
In randomised, double-blind trials the proportion of 
patients meeting the primary endpoint (a headache 
response at 2 h) was consistently found to be significantly 
higher among those taking frovatriptan as opposed to 
placebo. Three crossover trials compared early adminis-
tration of frovatriptan 2.5 mg with almotriptan 12.5 mg, 
rizatriptan 10  mg and zolmitriptan 2.5  mg in patients 
with migraine. No significant between-group differences 
emerged in patient drug preference scores (primary end-
point) or in other endpoints, except for headache recur-
rence, which in two of the trials favoured frovatriptan 
(Sanford 2012). Frovatriptan was generally better toler-
ated than all four triptan comparators. In just one trial it 
failed to show the same efficacy as sumatriptan. Admin-
istration of frovatriptan early on in an attack, while the 
pain is still mild, was found to be more effective than late 
administration. In clinical trials frovatriptan appeared to 
show a more sustained treatment effect, having the long-
est plasma half-life (26 h) and the lowest recurrence rate 
at 24  h (7–25  %). Furthermore, it was better tolerated 
than the comparators.
Frovatriptan is recommended by a number of national 
guidelines for the perimenstrual prevention of menstrual 
attacks in women with pure menstrual migraine (MM) or 
menstrually related migraine (MacGregor 2014).
Almotriptan
Large RCTs have shown that almotriptan 12.5  mg pro-
vides optimal pain relief and tolerability. Almotriptan 
effectively improved pain relief at 2 h, reduced migraine-
associated symptoms, and showed low recurrence rates. 
These findings were replicated in patient subgroups, 
such as adolescents and women with MM. These tri-
als also showed that outcomes were better if patients 
took almotriptan early, when the pain was still mild. The 
clinical evidence collected and the comparisons made 
in the course of a decade of use have demonstrated that 
almotriptan is one of the more effective and fast-acting 
triptans available, showing a placebo-like tolerability pro-
file (Antonaci et  al. 2010; Pascual et  al. 2010). The pos-
sibility of administering almotriptan via iontophoretic 
transdermal patch has also been raised (Calatayud-Pas-
cual et al. 2011).
All the triptans are indicated (level A recommendation) 
for the acute treatment of moderate-to-severe migraine 
and mild-to-moderate migraine responding poorly to 
NSAIDs or combinations of analgesics, and mild-to-
moderate migraine in patients with contraindications, 
intolerance or hypersensitivity to NSAIDs. The triptans 
are effective in about 60 % of NSAID non-responders.
Although most triptans are effective when adminis-
tered orally, they are available in various formulations 
(tablets, oral dispersible tablets, nasal spray, subcutane-
ous injection, suppositories). Sumatriptan is the most 
flexible triptan in this sense, being available in subcuta-
neous injection, oral tablet, nasal spray, oral dispersible 
tablet and suppository forms.
The choice of triptan and formulation depends on the 
individual patient’s characteristics, preferences and head-
ache features, as well as on convenience and cost consid-
erations. The single patient’s response to a triptan cannot 
be predicted. The triptans are most beneficial if they are 
taken at the very onset of headache (Belvís et al. 2014).
Headache recurrence can occur in 15–40 % of patients 
taking oral triptans.
The efficacy of the triptans, in cases in which switching 
between triptans has failed to produce the desired effec-
tiveness, could be improved by adding an NSAID.
All the triptans show similar side effects, but these are 
more marked when they are administered subcutane-
ously. Side effects may be mitigated by switching to a 
different triptan or choosing another route of administra-
tion. The most common triptan side effects are known as 
‘triptan sensations’ and they include paraesthesias, flush-
ing, tingling, neck pain and mild transient chest pressure. 
Although rare, cardiovascular complications have also 
been reported as the triptans can activate the (5-HT2A) 
receptor in peripheral arteries. The incidence of cardiac 
arrhythmias, myocardial infarct and stroke is about 1 in 
1,000,000 patients under triptan treatment.
No association between triptan use and cardiovascular 
risk emerged from a systematic review of observational 
studies (Dodick et al. 2004). Similarly, a cohort study that 
included 13,664 migraine patients who were receiving a 
triptan found no association between triptan prescrip-
tion and stroke, other cardiovascular events or death 
(Hall et al. 2004). However, in this cohort, triptans were 
prescribed to patients at less risk of these events. To date, 
few comparative observational studies have investigated 
the cardiovascular safety of migraine-specific drugs in 
clinical practice. On the basis of the available evidence, 
the triptans do not seem to be associated with major car-
diovascular safety issues, although the evidence on stroke 
risk is conflicting. However, it has been suggested that if 
an increase of the absolute stroke risk in recently exposed 
patients does exist, it must be small (Roberto et al. 2015).
Acute migraine treatment with triptans is contraindi-
cated in various circumstances, listed in Table 4. It should 
be noted that when treating cases of migraine with typi-
cal aura, triptans should be taken when the pain begins 
and not in the aura phase (Table 4).
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The administration of other vasoconstrictors, such as 
ergotamine and its derivatives, and also of other triptans, 
is contraindicated within 24 h of taking a triptan.
Worldwide, sumatriptan and zolmitriptan have been 
approved only as nasal formulations for the treatment of 
migraine attacks in children older than 12 years. In addi-
tion, in the US, the use of oral almotriptan is approved in 
children older than 12 years, and oral rizatriptan 5 mg in 
children older than 6 years.
The development of MOH is a risk with all the triptans, 
which, therefore, must not be taken on more than 10 days 
per month (Headache Classification Committee of the 
International Headache Society (IHS) 2013). Litera-
ture data suggest that the mean time to onset of MOH 
is 1.7  years for triptan users, 2.7  years for patients tak-
ing ergots, and 4.8 years for those using analgesics (Lim-
mroth et al. 2002).
General principles of preventive treatment
Successful management of migraine rests on an effective 
alliance between the doctor and the patient, and on effec-
tive patient education: the diagnosis must be carefully 
explained to the patient from the outset and it must be 
properly understood. In this way, realistic expectations 
can be set. Patient-compiled headache diaries can be very 
valuable tools for planning and evaluating treatment. The 
availability of a carefully kept record of days with head-
ache, pain severity, medication use and response, as well 
as obvious triggers (e.g., menstruation), can be vital in 
determining the need for preventive strategies and in 
evaluating therapeutic outcomes (Antonaci et  al. 2011). 
Disability scales, such as the Migraine Disability Assess-
ment Score (MIDAS) (Stewart et al. 1999), are important 
instruments for evaluating the impact of headache on a 
patient’s daily life. The Headache Under-Response to 
Treatment questionnaire allows even non-expert clini-
cians to measure the effectiveness of a headache treat-
ment (Westergaard et al. 2013).
Migraine is a highly heterogeneous condition (Nappi 
et  al. 2000) and its treatment should be tailored to the 
individual patient. After explaining the diagnosis, the 
physician should encourage the patient to actively par-
ticipate in assessing how his/her lifestyle and behaviours 
(i.e. diet, sleep, exercise, avoidance of migraine-triggering 
factors) may contribute to his/her condition; patients 
should also be encouraged to explore non-pharmacolog-
ical approaches whose effectiveness in migraine preven-
tion is well documented, such as biofeedback, relaxation 
therapy and cognitive behavioural therapies.
There is some recent evidence of the effectiveness of 
behavioural interventions to supplement drug therapy 
with relaxation and cognitive behavioural therapy (CBT). 
Relaxation training (deep breathing) was easily adopted 
and often used post intervention. The CBT components 
were mainly viewed positively but regarded as more chal-
lenging to learn and implement in migraine (Morgan 
et al. 2015).
Although there are no sound and established criteria 
for choosing one prophylactic drug over another, there 
are various aspects and considerations that should be 
taken into account in order to weigh up the risk-benefits 
ratio: comorbidities, drug interactions, contraception, 
possible side effects, patient expectations, cost (Table 5).
The US Headache Consortium defined the following 
goals for preventive treatment: (1) to decrease attack fre-
quency by 50 % and decrease attack intensity and dura-
tion; (2) to improve responsiveness to acute therapy; (3) 
to improve function and decrease disability; and (4) to 
prevent the occurrence of MOH and chronic daily head-
ache (Silberstein et  al. 2012a). In general, a preventive 
treatment may be considered warranted (Lipton et  al. 
2007) when migraine attacks occur on 4 or 5 days per 
month with normal functioning, or when a patient expe-
riences 2–3 migraine days per month with some impair-
ment or disability.
The initiation of a preventive migraine therapy must 
be preceded by a discussion with the patient, who must 
be made aware of the treatment plan, the risk of side 
Table 4 Contraindications of triptans
Avoid triptans in the presence of:
 untreated arterial hypertension
 coronary heart disease
 Raynaud’s disease
 a history of ischaemic stroke
 pregnancy, breastfeeding
 severe liver or kidney failure
 age ≥ 65 years
 basilar or hemiplegic migraine
Table 5 Crucial points in migraine therapy management
Educational programme Avoid migraine-triggering factors
Monitoring attacks Diary
Disability and outcome evaluation Self-administered questionnaire
Non-pharmacological strategies Relaxation therapy
Biofeedback
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effects, and the duration of the proposed treatment. 
Drugs should be started at a low dose and slowly up-
titrated until a therapeutic effect is seen, the maximum 
dose is achieved, or side effects become intolerable. All 
drugs should be trialled at an adequate dose for at least 
6–8 weeks before being deemed ineffective (Freitag and 
Shumate 2014). Most patients need to be treated for at 
least 6 months in order to control their migraines; there-
after the drug can be gradually withdrawn.
Preventive treatment will not stop all attacks (two-
thirds of patients can expect a 50  % reduction in head-
ache frequency and patients need to understand that they 
will still need acute medication) (Table 6).
Pharmacological migraine prevention
Various drug classes are used for migraine prophylaxis, 
and several clinical practice guidelines have been pub-
lished in the US and in Europe. Despite some differences, 
these are based on the same general principles.
The drugs of first choice in the US are three beta blockers 
(propranolol, timolol and metoprolol), and two antiepilep-
tic drugs (divalproex sodium and topiramate). Onabotuli-
numtoxinA has also been approved for use in the treatment 
of chronic migraine, but not episodic migraine.
As regards the beta adrenergic blockers, propranolol (at 
doses of 80–240 mg per day), timolol (10–15 mg twice a 
day) and metoprolol (50–200 mg per day) are effective in 
migraine prophylaxis (Silberstein et  al. 2012a). They are 
associated with a range of possible side effects: fatigue, 
sleep disorders, depression, decreased exercise tolerance 
and, less commonly, orthostatic hypotension, significant 
bradycardia and impotence.
Contraindications to treatment with these drugs 
include: congestive heart failure, asthma and insulin-
dependent diabetes. Since metoprolol at doses of less 
than 200  mg per day preserves its beta-1 selectivity, it 
may be suitable for some patients with asthma and dia-
betes mellitus.
Several studies have shown the non-specific calcium 
channel blocker flunarizine to be effective in migraine 
prophylaxis at doses of 5–10 mg per day. Weight gain and 
depression are possible side effects. This drug is not avail-
able in the USA, but it is commonly used in some Euro-
pean countries, in Canada and in South America (Evers 
et al. 2009; Pringsheim et al. 2012).
As already indicated, antiepileptic drugs are also used 
in the prophylactic treatment of migraine. Divalproex 
sodium at doses of 500–1000  mg per day shows good 
efficacy and tolerability; its possible side effects are 
weight gain, hair loss and tremor. Valproate is a severely 
teratogenic drug and not be used as first-line migraine 
prophylaxis in women of child-bearing age. Topiramate is 
effective at doses of 100 mg per day, and has been studied 
in chronic migraine (Lipton and Silberstein 2015) versus 
placebo. Its possible side effects include behavioural or 
cognitive disturbances, impaired vision due to increased 
intraocular pressure, weight loss, renal stone formation, 
and a tingling or prickling sensation in the hands and 
feet. Most adverse events are minimised by titrating the 
dose by 25 mg per week to reach the target dose. Topira-
mate has been associated with cleft palate in newborns 
whose mothers used the drug during the first trimester of 
pregnancy and therefore cannot be considered the first-
choice drug in women of child-bearing age.
OnabotulinumtoxinA is the only agent specifically 
approved for the prevention of chronic migraine (Sil-
berstein et  al. 2013). It is extremely well tolerated. A 
comparative trial versus topiramate in chronic migraine 
(Cady et al. 2011) showed similar results, although fewer 
adverse events were recorded in the onabotulinumtoxinA 
group.
Optimal use of injectable onabotulinumtoxinA 
depends on accurate delivery of the toxin to the target, as 
well as use of the correct dose and adherence to the rec-
ommended number of injections per site and frequency 
of injections (Ashkenazi and Blumenfeld 2013). The drug 
is typically injected across 31 sites on the head and neck 
(injected muscles include the procerus, bilateral corruga-
tors, frontalis, temporalis, occipitalis, cervical paraspinal, 
and superior trapezius muscles). The recommended dose 
is 155 units administered intramuscularly (5 units per 
site), with retreatment every 12 weeks (Pringsheim et al. 
2012).
A recent doses comparison study with Onabotuli-
numtoxinA in a real-life clinical setting demonstrated 
the superior efficacy of OnabotulinumtoxinA 195 U 
compared to 155 U in CM patients with MOH during 
a 2-year treatment period with similar safety and toler-
ability profile (Negro et al. 2015a). In a later contribution 
(2-years treatment) with OnabotulinumtoxinA 155 U 
it has been confirmed the efficacy and safely in chronic 
migraine but also in patients affected with and medica-
tion overuse headache (Negro et al. 2015b).
Table 6 Take‑home message for optimal prevention
Involve patients in their care to improve adherence
Consider comorbidities and, when possible, choose a single medication 
to treat multiple comorbid disorders
When the patient is a woman of childbearing age, discuss contraception 
and the potential risk of medication use during pregnancy
Start at a low dose
Give each preventive medication at an adequate dose and for an 
adequate time (6–8 months)
Avoid interfering, contraindicated or overused medications
Re-evaluate the therapy; follow-up is important
Page 9 of 14Antonaci et al. SpringerPlus  (2016) 5:637 
Finally, since studies of treatment with antidepressants 
were small, this category of drugs was not assigned a 
recommendation level A. That said, amitriptyline (doses 
of 10–150  mg per day), fluoxetine (doses of 10–40  mg 
per day) and venlafaxine extended release (doses of 
75–150  mg per day) seem to be effective (Evers et  al. 
2009).
Treatment in children and adolescents
The efficacy and safety of acute or preventive medica-
tions in children and adolescents are poorly documented. 
It goes without saying that these are two populations in 
which non-pharmacological approaches should be pre-
ferred. However, when a pharmacological therapy is war-
ranted in a child or adolescent, the general principles 
are the same as those outlined for adults (Termine et al. 
2011).
Symptomatic therapy
A systematic review found acetaminophen (dose: 15 mg/
kg) and ibuprofen (7.5–10 mg/kg) to be safe and effective 
in children (Lewis et al. 2004).
Worldwide, sumatriptan and zolmitriptan has been 
approved only as nasal formulations for the treatment of 
migraine attacks in children older than 12 years. In addi-
tion, in the US, the use of oral almotriptan is approved in 
this group, while oral rizatriptan 5 mg is approved for use 
in children older than 6 years of age (Evers 2013).
Preventive therapy
Only two agents have been shown in multiple controlled 
trials to be effective in migraine prophylaxis in this age 
group: flunarizine 5 mg per day, which can be adminis-
tered in the early evening to overcome the problem of 
daytime sleepiness, and topiramate. Topiramate effec-
tively reduced headache frequency, severity and duration. 
The most common side effects reported were weight loss, 
cognitive problems and sensory disturbances (Lewis et al. 
2004).
Novel acute and preventive treatments
Recent years have seen the emergence of novel acute and 
preventive migraine treatments that target different neu-
ral mechanisms and/or act via innovative delivery sys-
tems (Rapoport 2011).
Calcitonin gene‑related peptide antagonists (gepants)
Calcitonin gene-related peptide (CGRP) is a neuro-
peptide implicated in the pathophysiology of migraine. 
Recent evidence suggests that the brainstem is the site of 
the key dysfunctions underlying migraine. It is thought 
that cortical changes, brainstem changes, or both, lead 
to activation of the trigeminal system. When this occurs, 
neuropeptides such as CGRP are released from trigemi-
nal nerve endings in the meninges, inducing vasodilata-
tion and triggering sensory trigeminal pain.
The CGRP blockers or receptor antagonists, also 
known as the “gepants” or monoclonal antibodies, are 
an interesting group of molecules which are emerging 
as possible new treatments for migraine. Unlike conven-
tional treatments, they do not have a vasoconstrictive 
effect (Tso and Goadsby 2014) and, contrary to the cur-
rent preventive strategies, they are able to target specific 
migraine mechanisms. They also represent the most pro-
lific class: multiple agents targeting either CGRP itself or 
its receptor are under development for both acute and 
preventive migraine treatment.
Considering that CGRP receptor antagonists (CGRP-
RAs) are the first non-serotoninergic, migraine-specific 
drugs without a vasoconstrictor action, it has been sug-
gested that they may be suitable for patients with vascular 
disease, such as coronary artery disease and peripheral 
vascular disease (Tso and Goadsby 2014).
Five distinct CGRP-RAs (telcagepant, MK-3207, 
olcagepant, BMS-927711, BI44370TA, NCT01613248) 
have shown proof of efficacy for the treatment of 
migraine, but in all cases the trials were discontinued for 
various reasons, including concerns over the risk of liver 
toxicity with frequent use.
Telcagepant has been studied as a preventive therapy 
in a parallel-group RCT in episodic migraine patients. 
Although this trial, too, was terminated early due to con-
cerns over hepatotoxocity, the limited data produced 
pointed to a larger reduction in mean migraine/probable 
migraine days in the telcagepant groups versus placebo 
(Ho et al. 2014).
Recently anti-GCRP antibodies (ALD-403, LY-2951742, 
LBR-101) have been developed as a means of remov-
ing the excess CGRP that is released from perivascu-
lar trigeminal nerve endings. Monoclonal antibodies 
against CGRP receptor (e.g. AMG-334) have also been 
developed to block the receptor from signalling trans-
mission. The development of monoclonal antibodies 
against CGRP and its receptor may be seen as an illustra-
tion of how translational research is becoming part of a 
new approach to migraine prevention (Bigal et al. 2015). 
Data from phase I and II studies show the efficacy of 
these molecules versus placebo in episodic and chronic 
migraine (de Hoon et al. 2013).
Serotonin 5HT1F agonists (ditans)
Another interesting drug is lasmiditan (COL-144), a 
selective 5-HT1F agonist at the receptor that has shown 
good efficacy and tolerability as an acute treatment in two 
RCTs (intravenous and oral administration) (CoLucid 
Pharmaceuticals 2008). Activation of 5-HT1F receptors 
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decreases the expression of c-Fos, a marker of neuronal 
activation, in the trigeminal nucleus caudalis, without 
having vascular effects. In a randomised, phase II trial 
lasmiditan performed better than placebo at the highest 
doses. The most common adverse event was dizziness, 
present in up to 38 % of patients (Farkkila et al. 2012).
Glutamate receptor antagonists
Glutamate, which is released from neurons expressing 
5-HT1B/1D/1F receptors in the trigeminal ganglia, is 
implicated in aspects of both migraine and migraine aura 
pathophysiology, including trigeminovascular activa-
tion, central sensitisation and cortical spreading depres-
sion (Andreou and Goadsby 2009; Ramadan 2003). 
There are three glutamate receptor subtypes: N-methyl-
d-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-
isoazolepropionic acid (AMPA), and kainate.
Some glutamate antagonists (tezampanel, LY-293558, 
and ADX10059) have shown effectiveness versus pla-
cebo in the acute treatment of migraine without aura. 
ADX10059 was studied in a multicentre migraine pre-
vention study that was terminated early following the 
emergence of a higher than expected rate of liver enzyme 
abnormalities (Chan and MaassenVanDenBrink 2014).
Since it is known that NMDA receptors are activated 
or inhibited by neuroactive compounds generated by 
tryptophan metabolism through the kynurenine pathway, 
recent findings showed serum levels of all kynurenine 
metabolites altered in patients with chronic migraine and 
cluster headache (Curto et  al. 2015). Infact a reduction 
in kynurenic acid levels was shown in patients affected 
by chronic migraine as well as an increase in serum 
xanthurenic acid, such finding has been interpreted as 
a defensive mechanism aimed at reducing the extent of 
headache in migraine.
The increasing number of preclinical data that high-
light the importance of the kynurenine pathway in the 
pathophysiology and treatment of chronic headache dis-
orders may open new therapeutic perspectives (Curto 
et al. 2015).
Orexin receptor antagonists (rexants)
Orexin A and B are neuropeptides that are synthesised in 
the hypothalamus and thought to play a role in nocicep-
tion. Originally developed to treat insomnia, filorexant is 
a dual orexin receptor (1 and 2) antagonist that has com-
pleted a phase IIa trial for the prophylaxis of migraine 
(NCT01513291); however, it was found to be ineffective 
(Chabi et al. 2015).
Nitric oxide synthase inhibitors
Nitric oxide synthase (NOS) produces nitric oxide, a 
gaseous vasodilator that may activate trigeminovascular 
fibres, triggering the release of CGRP. Neuronal NOS and 
inducible NOS inhibitor were not found to be effective 
for acute or preventive migraine treatment (Palmer et al. 
2009; Hoivik et al. 2010).
Neuromodulation
Occipital nerve stimulation (ONS) with implanted leads 
was studied as a possible treatment for chronic migraine 
in the multicentre ONSTIM trial (Silberstein et  al. 
2012b). However, no significant difference was found in 
the primary outcome (50  % reduction of pain severity) 
between the patients randomised to active stimulation 
(n  =  105) and the sham stimulation patients (n  =  52). 
In addition, the authors reported a high rate of device-
related adverse events: lead migration occurred in 18.7 % 
of patients and persistent pain or numbness at the lead 
site in 21.5 % (Silberstein et al. 2012b). Different results 
were obtained in recent contribution with paresthesia-
free cervical 10 kHz spinal cord stimulation at 24 weeks 
of treatment of 17 patients suffering from resistent 
chronic migraine. Half of the subjects reported a >30 % 
reduction in headache days, 36  % reported a reduction 
greater than 50 %, and eight subjects reverted to an epi-
sodic migraine pattern. Medication intake reduced sig-
nificantly, and four subjects discontinued triptans use 
at 6-month follow-up. The significant reduction in the 
number of headache days in the studied population at 
6  months, the relative high number of ‘responders’ and 
the substantial decrease in the headache-specific ques-
tionnaires scores compares favourably to results seen in 
studies with ONS (Arcioni et al. 2016).
Interest thus turned to non-invasive neurostimulation 
devices. In this context, however, efficacy studies versus 
sham are problematical as the stimulation may produce 
paresthesias or pain.
Transcranial magnetic stimulation (TMS) is another 
neuromodulation technique. TMS uses a fluctuat-
ing magnetic field to induce, in the underlying cortex, 
an electrical current that is thought to disrupt cortical 
spreading depression (Tso and Goadsby 2014).
Neurostimulation
Cefaly is a device with supraorbital transcutaneous 
stimulation properties that shows efficacy in migraine 
prevention (Arcioni et al. 2016). It is safe and well toler-
ated: in a survey of 2313 users, only 4.3 % reported minor 
adverse events and even fewer (2 %) had to discontinue 
its use (Magis et al. 2013). Positive results have been con-
firmed also in patients experiencing a low frequency of 
attacks, showing significant improvements in multiple 
migraine severity parameters following a brief period of 
high frequency tSNS. Therefore, tSNS may be considered 
a valid option for the preventive treatment of migraine 
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attacks in patients who cannot or are not willing to take 
daily medications, or in whom low migraine frequency 
and/or intensity would not require pharmacological pre-
ventive therapies (Russo et al. 2015).
Single‑pulse transcranial magnetic stimulation
The Cerena Transcranial Magnetic Stimulator is a hand-
held device that applies single pulses of TMS to the back 
of the head. The device is indicated for the acute treat-
ment of migraine with aura and indeed received FDA 
approval for this indication in December 2013. However, 
due to its large size it is not available to patients. A simi-
lar, but smaller device, the Spring TMS (manufactured 
by eNeura) has also been approved by the FDA for use in 
patients with migraine with aura. The device is for adults 
(patients aged ≥18  years) and it should not be used for 
more than one treatment in 24 h. The device must not be 
used by patients who have magnetic metals in their head, 
neck or upper body or by people with pacemakers, deep 
brain stimulators or other types of implanted device. 
Patients with suspected or diagnosed epilepsy or a per-
sonal or family history of seizures should also avoid this 
treatment.
GammaCore is a handheld device used for the acute 
and preventive treatment of migraine. By generating an 
electrical signal it delivers transcutaneous vagal nerve 
stimulation (VNS). A conductive gel is applied on the 
stimulation surfaces of the device and it is held against 
the neck. Each dose takes approximately two minutes to 
administer. VNS can suppress high glutamate levels in 
the trigeminal nucleus caudalis, and this may be the pain-
blocking mechanism of non-invasive VNS (Oshinsky 
et al. 2014; Ambrosini et al. 2015). In a recent contribu-
tion a clinically meaningful response was observed after 
3  months of prophylactic nVNS therapy in treatment-
refractory migraine (both episodic and chronic) popula-
tion. VNS was associated with significant reductions in 
pain intensity and number of headache days per month 
(Kinfe et al. 2015). Similar positive results were obtained 
in the acute treatment of high frequency episodic and 
chronic migraine that may help to reduce medication 
overuse and medication-associated adverse events (Bar-
banti et al. 2015).
Besides, transcutaneous stimulation of the auricu-
lar branch of the vagal nerve (t-VNS) has been used in 
the treatment of chronic migraine (Straube et  al. 2015). 
A monocentric, randomized, controlled, double-blind 
study was conducted showing that the procedure was 
safe and effective. The mean reduction of headache days 
after 12  weeks of treatment exceeded that reported for 
other nerve stimulating procedures.
Sphenopalatine ganglion stimulation
In view of the reported preventive effect of sphenopala-
tine ganglion stimulation in cluster headache, trials are 
now underway to explore the efficacy of this method as 
a possible preventive treatment of chronic migraine (Tso 
and Goadsby 2014; Khan et al. 2014).
Conclusion
In summary, appropriate and patient-tailored migraine 
treatments can be identified only by evaluating five key 
aspects, according to the following decision-making 
pathway:
1. the level of attack frequency and disability (six or 
more headache days per month, more than four 
headache days with moderate disability, more than 
three headache days with impairment);
2. the suitability of acute therapy in the single patient 
(i.e. whether it is contraindicated, whether it pro-
duces adverse events, and whether or not it produces 
adequate relief );
3. the possible inefficacy of non-pharmacological 
therapy, or the patient’s unwillingness to use such 
approaches;
4. the presence of specific migraine forms (basilar, 
hemiplegic and prolonged aura migraine);
5. the presence of medical or psychiatric comorbidities.
In this way, the numerous variables that can modify 
the final approach (e.g. individual response, tolerability, 
patient preference and clinical aspects) are taken into 
account and concomitant medical or psychological con-
ditions can be addressed and treated. It is also important 
to introduce measures aimed at reducing the biologi-
cal tendency to headaches, but also to ensure that the 
patient has realistic expectations as regards what can be 
achieved. It is particularly important to identify and ade-
quately treat patients affected by chronic migraine, given 
that this is a highly disabling but treatable clincal entity.
Since the therapeutic choice in migraine is quite elderly, 
pending the development of new acute and preventive 
options for migraine, our existing therapeutic armamen-
tarium offers several options to be explored by clinicians 
in their efforts, working together with patients, to tackle 
the disability associated with migraine and improve the 
lives of migraine sufferers (Giamberardino and Martel-
letti 2015; Sabato et al. 2015; Martelletti 2015).
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